A Ciccullo
Overview
Explore the profile of A Ciccullo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iannone V, Lombardi F, Ciccullo A, Lamanna F, Salvo P, Sanfilippo A, et al.
AIDS Behav
. 2025 Jan;
PMID: 39779624
The new Cabotegravir + Rilpivirine long acting (CAB + RPV) is the injectable regimen for treatment-experienced people with HIV (PWH). Little data from real-world settings are available, particularly in more...
2.
Passerotto R, Lamanna F, Salvo P, Iannone V, Steiner R, Carbone A, et al.
Antivir Ther
. 2024 Dec;
29(6):13596535241306467.
PMID: 39698926
Introduction: BIC/FTC/TAF showed efficacy and tolerability in randomized trials as a switch strategy in virologically-suppressed people living with HIV. We evaluated its effectiveness in a real-life setting. Methods: A retrospective...
3.
Ciccullo A, Baldin G, Borghi V, Cossu M, Giacomelli A, Lagi F, et al.
J Antimicrob Chemother
. 2022 Oct;
78(1):117-121.
PMID: 36272137
Objectives: We aimed to investigate and compare the efficacy and safety of two dolutegravir-based two-drug regimens: dolutegravir + lamivudine versus dolutegravir + rilpivirine. Methods: We analysed a cohort of people...
4.
Tosato M, Varone F, Ciccullo A, Calvani R, Moschese D, Potenza A, et al.
J Frailty Aging
. 2020 Dec;
10(1):70-71.
PMID: 33331625
COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, showed higher severity and lethality in male older adults . There are currently no specific treatments. Studies...
5.
Borghetti A, Ciccullo A, Lombardi F, Baldin G, Belmonti S, Prosperi M, et al.
HIV Med
. 2020 Sep;
22(1):22-27.
PMID: 32964671
Objectives: Nucleoside reverse transcriptase inhibitor (NRTI) transmitted drug resistance mutations (TDRMs) could increase the risk of virological failure (VF) of first-line integrase strand transfer inhibitor (InSTI)-based regimens. Methods: Patients starting...
6.
Ciccullo A, Borghetti A, Dusina A, Segala F, Visconti E, Tamburrini E, et al.
HIV Med
. 2020 Sep;
22(1):e3-e4.
PMID: 32876390
No abstract available.
7.
Borghetti A, Ciccullo A, Paratore M, Rovedi F, Stella L, Marchetti A, et al.
J Infect
. 2020 May;
82(1):159-198.
PMID: 32473233
No abstract available.
8.
Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, et al.
HIV Med
. 2019 Jun;
20(9):624-627.
PMID: 31240860
Objectives: Two-drug antiretroviral regimens based on lamivudine (3TC) plus either a protease inhibitor (PI) or dolutegravir (DTG) are becoming increasingly popular in switch strategies. Our goal was to derive a...
9.
Bellino S, Borghetti A, Lombardi F, Camoni L, Ciccullo A, Baldin G, et al.
Epidemiol Infect
. 2019 Mar;
147:e89.
PMID: 30869037
Here we evaluated hospitalisation rates and associated risk factors of human immunodeficiency virus (HIV)-infected individuals who were followed up in an Italian reference hospital from 1998 to 2016. Incidence rates...
10.
Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu M, et al.
HIV Med
. 2018 Nov;
20(2):164-168.
PMID: 30457197
Objectives: The aim of the study was to compare the efficacy and tolerability of switching antiretroviral therapy to dolutegravir + emtricitabine/tenofovir disoproxil fumarate (TDF) with those of switching to elvitegravir/cobicistat/emtricitabine/TDF...